Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
What bowel dose constraint do you recommend if you are boosting a pelvic lymph node for prostate cancer?
Do you have a maximum bowel dose constraint?
Answer from: Radiation Oncologist at Community Practice
We generally use 55 Gy to < 5 cc based on Gyne literaturem and try to make sure the high prescribed dose is limited to one wall of bowel loop.
Comments
Radiation Oncologist at Torrance Memorial Medical Center
@Sushil Beriwal, could you share a paper or protoc...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is the one I was referring to. It’s a s...
2752
2753
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
60 to 66 Gy at 2 Gy per fraction.
Sign in or Register to read more
6526
6532
Related Questions
When following active surveillance paradigm, what PSA increase will trigger prostate biopsy?
For a patient with stage IIB pure seminoma s/p orchiectomy who has bilateral RP adenopathy, do you also cover the contralateral iliac nodes in the dog-leg field?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
How do you approach elective nodal irradiation in muscle-invasive bladder cancer?
What dose-fractionation do you use for salvage HDR brachytherapy for biopsy proven locally recurrent prostate cancer after prior external beam radiotherapy?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
In light of the recent data indicating increased late grade 3 to 5 toxicities (LTOX3) after hypofractionated salvage radiation therapy, will you continue to offer these regimes to patients?
How would you manage an aortocaval nodal recurrence of prostate cancer in a patient who previously received salvage radiation to the fossa and pelvic nodes?
How would you optimally boost patients with high or very high risk prostate cancer receiving definitive radiotherapy in 2025?
@Sushil Beriwal, could you share a paper or protoc...
This is the one I was referring to. It’s a s...